Skip to main content
DAEWON PHARMACEUTICAL CO.,LTD logo

DAEWON PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 003220 ISIN · KR7003220001 KO Manufacturing
Open in API
Filings indexed 300 across all filing types
Latest filing 2021-03-19 Declaration of Voting R…
Country KR South Korea
Listing KO 003220

About DAEWON PHARMACEUTICAL CO.,LTD

https://www.daewonpharm.com/eng

Daewon Pharmaceutical Co., Ltd., established in 1958, is a pharmaceutical company focused on improving human health. The company specializes in the development and manufacturing of prescription drugs and finished pharmaceutical products. Its portfolio includes a range of medications such as antipyretics, analgesics, and treatments for respiratory and cardiovascular conditions. Daewon Pharmaceutical maintains a strong commitment to research and development, with a strategic focus on New Chemical Entities (NCE) and Incrementally Modified Drugs (IMD) to provide advanced healthcare solutions.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed during the meeting, including financial statement approval, dividend declarations, and the appointment of directors and audit committee members. This aligns perfectly with the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2021-03-19 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used in South Korea for reporting insider trading or changes in share ownership by company directors and executives. Based on the provided definitions, this falls under the 'Director's Dealing' category, which covers personal share transactions by company directors and executives.
2021-03-18 Korean
사업보고서 (2020.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Audit Report' (감사보고서) for Daewon Pharmaceutical Co., Ltd. for the fiscal year 2020. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes. It is not an Annual Report (10-K) as it focuses specifically on the audit and financial statements, nor is it an Earnings Release (ER) as it is a full audited report. Therefore, it falls under the 'Audit Report / Information' category. FY 2020
2021-03-12 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from Daewon Pharmaceutical titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion (unqualified/appropriate), key financial data (assets, liabilities, revenue, profit), and the name of the external auditor (Samjong KPMG). While it contains financial data, it is a summary disclosure of the audit results rather than the full annual report (10-K) or a standalone audit report document. In the context of Korean regulatory filings (DART/KIND), this specific format is the standard announcement of the receipt and submission of the audit report, which falls under the 'Audit Report / Information' category. FY 2020
2021-03-11 Korean
[기재정정]주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Convocation of the Annual General Meeting' (주주총회소집공고) for Daewon Pharmaceutical. It includes the meeting agenda, board activities, and financial highlights for the 60th fiscal year. While it contains financial information, it is primarily a proxy statement/notice sent to shareholders to inform them of the upcoming meeting and request their participation/votes. In the context of the provided filing types, this is classified as a Proxy Solicitation & Information Statement.
2021-03-09 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Daewon Pharmaceutical. It contains the meeting agenda, details on board activities, financial highlights, and proxy information for shareholders. This type of document is classified as a Proxy Solicitation & Information Statement (PSI) as it provides shareholders with the necessary information to vote on agenda items at the upcoming meeting.
2021-03-04 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.